Harnessing Antibody-Dependent Cellular Cytotoxicity To Control HIV-1 Infection.
ACS Infect Dis
; 5(2): 158-176, 2019 02 08.
Article
en En
| MEDLINE
| ID: mdl-30525453
ABSTRACT
Passive administration of broadly neutralizing anti-human immunodeficiency virus type 1 (HIV-1) antibodies (bNAbs) has been recently suggested as a promising alternative therapeutic approach for HIV-1 infection. Although the success behind the studies that used this approach has been attributed to the potency and neutralization breadth of anti-HIV-1 antibodies, several lines of evidence support the idea that specific antibody-dependent effector functions, particularly antibody-dependent cellular cytotoxicity (ADCC), play a critical role in controlling HIV-1 infection. In this review, we showed that there is a direct association between the activation of ADCC and better clinical outcomes. This, in turn, suggests that ADCC could be harnessed to control HIV-1 infection. To this end, we addressed the passive administration of bNAbs capable of selectively activating ADCC responses to HIV-1 patients. Finally, we summarized the potential barriers that may impede the optimal activation of ADCC during HIV-1 infection and provided strategic solutions to overcome these barriers.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Infecciones por VIH
/
Inmunización Pasiva
/
Anticuerpos Neutralizantes
/
Citotoxicidad Celular Dependiente de Anticuerpos
Límite:
Animals
/
Humans
Idioma:
En
Revista:
ACS Infect Dis
Año:
2019
Tipo del documento:
Article
País de afiliación:
Jordania